

NOTE: * No ClinicalTrials.gov webpage is available currently (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide

ETCTN Breast Cancer Trials (Open as of 11/10/2025)

Protocol Number	Phase	Protocol Title
10146	II	Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer
10449	I	A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer
10525	lb	A Phase 1b Trial of ZEN-3694 with Pembrolizumab and Nab- Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer
10546	I	Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer
10720	lb	Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients with HER2 Expressing Solid Tumors